Biosimilar medicines are revolutionary therapeutics that treat patients at a fraction of the cost of brand-name biologics. However, public awareness and trust of biosimilars is still evolving, meaning many patients and providers are overpaying for expensive brand-name biologics. To address this education gap, the Biosimilars Council launched a new, one-of-a-kind educational resource: the Biosimilars Patient Resource Center.
Everything You Need to Know About Biosimilars – All in One Place
The Biosimilars Patient Resource Center is a convenient site for answers to your pressing questions about biosimilar medicines. Whether you are a current or potential biosimilar or biologics patient, a caregiver, a medical professional, a policymaker, or if you just want to know more about biosimilars, the Biosimilars Patient Resource Center has information you can use.
As you browse through our new website, you will find a collection of up-to-date resources.
On the frequently asked questions page, you will find answers to common questions about biosimilars, from the most fundamental (what is a biosimilar?) to the more detailed (what does interchangeability mean?).
The stories page, includes stories from real patients who are living healthy, happy lives thanks to affordable biosimilars medicines. For example, Eileen, a 28-year-old musical theatre enthusiast in New York City, switched to a biosimilar after she lost insurance coverage for her biologic treatment for Crohn’s Disease.
We encourage you to check out the Biosimilars Patient Resource Center and other resources that can be found on our website. For more information about how you can join the biosimilars movement and advocate for greater access, visit our advocacy page.
Interested in sharing the Biosimilars Patient Resource Center with your network? View our social toolkit to find helpful assets for sharing on your digital and social channels.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.